Experienced in Bladder Cancer

Dr. Asha Karippot

Hematology | Oncology
Texas Health Resources
Texas Oncology - Plano West
4708 Alliance Blvd, Ste 150, 
Plano, TX 
On Staff At
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Bladder Cancer
Texas Health Resources
Texas Oncology - Plano West
4708 Alliance Blvd, Ste 150, 
Plano, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Asha Karippot is a Hematologist and an Oncologist in Plano, Texas. Dr. Karippot is rated as an Experienced provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Familial Pancreatic Cancer, and Paget Disease of the Breast.

Her clinical research consists of co-authoring 9 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Bladder Cancer.

Graduate Institution
Government Medical College - Thrissur (2002)
Residency
Icahn School of Medicine at Mount Sinai - Internal Medicine (2008)
Specialties
Hematology
Oncology
Licenses
Internal Medicine in OK
Fellowships
Seton Hall University School of Health and Medical (2011)
Seton Hall University School of Graduate Medical Education (2011)
Hospital Affiliations
Texas Health Allen
Languages Spoken
English
Hindi
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

Texas Oncology - Plano West
4708 Alliance Blvd, Ste 150, Plano, TX 75093
Call: 972-596-7801

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study)
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Procedure, Biological
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 2
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Colorectal Cancer Metastatic dMMR/MSI-H Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-Line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 17, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Phase: Phase 3
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: June 11, 2025
Intervention Type: Drug
Study Drugs: Cisplatin, Gemcitabine, Nab-Paclitaxel
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 3
View 4 Less Clinical Trials

9 Total Publications

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 19, 2024
View All 9 Publications
Similar Doctors
Advanced in Bladder Cancer
Dr. Revathi Angitapalli
Oncology | Hematology
Advanced in Bladder Cancer
Dr. Revathi Angitapalli
Oncology | Hematology

The Center For Cancer And Blood Disorders

515 West Mayfield Road, Suite 102, 
Arlington, TX 
 (28.1 miles away)
817-960-6100
Experience:
26+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Revathi Angitapalli is a Hematologist and an Oncologist in Arlington, Texas. Dr. Angitapalli has been practicing medicine for over 26 years and is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Chromophobe Renal Cell Carcinoma, and Clear Cell Sarcoma.

Advanced in Bladder Cancer
Dr. Waddah Arafat
Oncology
Advanced in Bladder Cancer
Dr. Waddah Arafat
Oncology

University Of Texas Southwestern Medical Center At Dallas

5200 Harry Hines Blvd, 
Dallas, TX 
 (14.2 miles away)
214-590-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Waddah Arafat is an Oncologist in Dallas, Texas. Dr. Arafat is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Testicular Cancer, Muscle Invasive Bladder Cancer, Prostate Cancer, Familial Prostate Cancer, and Orchiectomy.

Advanced in Bladder Cancer
Dr. Tian Zhang
Oncology
Advanced in Bladder Cancer
Dr. Tian Zhang
Oncology

University Of Texas Southwestern Medical Center At Dallas

2201 Inwood Rd, 
Dallas, TX 
 (13.7 miles away)
214-645-0624
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tian Zhang is an Oncologist in Dallas, Texas. Dr. Zhang is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), WT1-Related Wilms Tumor Syndromes, and Clear Cell Sarcoma.

VIEW MORE BLADDER CANCER DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Karippot's expertise for a condition
ConditionClose
    • Distinguished
    • Breast Cancer
      Dr. Karippot is
      Distinguished
      . Learn about Breast Cancer.
      See more Breast Cancer experts
    • Colorectal Cancer
      Dr. Karippot is
      Distinguished
      . Learn about Colorectal Cancer.
      See more Colorectal Cancer experts
    • Familial Colorectal Cancer
      Dr. Karippot is
      Distinguished
      . Learn about Familial Colorectal Cancer.
      See more Familial Colorectal Cancer experts
    • Familial Pancreatic Cancer
      Dr. Karippot is
      Distinguished
      . Learn about Familial Pancreatic Cancer.
      See more Familial Pancreatic Cancer experts
    • Paget Disease of the Breast
      Dr. Karippot is
      Distinguished
      . Learn about Paget Disease of the Breast.
      See more Paget Disease of the Breast experts
    • Advanced
    • Anal Cancer
      Dr. Karippot is
      Advanced
      . Learn about Anal Cancer.
      See more Anal Cancer experts
    • Cholangiocarcinoma (Bile Duct Cancer)
      Dr. Karippot is
      Advanced
      . Learn about Cholangiocarcinoma (Bile Duct Cancer).
      See more Cholangiocarcinoma (Bile Duct Cancer) experts
    • Diffuse Large B-Cell Lymphoma (DLBCL)
      Dr. Karippot is
      Advanced
      . Learn about Diffuse Large B-Cell Lymphoma (DLBCL).
      See more Diffuse Large B-Cell Lymphoma (DLBCL) experts
    • Follicular Lymphoma
      Dr. Karippot is
      Advanced
      . Learn about Follicular Lymphoma.
      See more Follicular Lymphoma experts
    • Gastroesophageal Junction Cancer
      Dr. Karippot is
      Advanced
      . Learn about Gastroesophageal Junction Cancer.
      See more Gastroesophageal Junction Cancer experts
    • Gastrointestinal Stromal Tumor
      Dr. Karippot is
      Advanced
      . Learn about Gastrointestinal Stromal Tumor.
      See more Gastrointestinal Stromal Tumor experts
    View All 16 Advanced Conditions
    • Experienced
    • Acute Monoblastic Leukemia (AmoL)
      Dr. Karippot is
      Experienced
      . Learn about Acute Monoblastic Leukemia (AmoL).
      See more Acute Monoblastic Leukemia (AmoL) experts
    • Adenoid Cystic Carcinoma
      Dr. Karippot is
      Experienced
      . Learn about Adenoid Cystic Carcinoma.
      See more Adenoid Cystic Carcinoma experts
    • Adult Immune Thrombocytopenia
      Dr. Karippot is
      Experienced
      . Learn about Adult Immune Thrombocytopenia.
      See more Adult Immune Thrombocytopenia experts
    • Adult Soft Tissue Sarcoma
      Dr. Karippot is
      Experienced
      . Learn about Adult Soft Tissue Sarcoma.
      See more Adult Soft Tissue Sarcoma experts
    • Agranulocytosis
      Dr. Karippot is
      Experienced
      . Learn about Agranulocytosis.
      See more Agranulocytosis experts
    • ALK-Positive Non-Small Cell Lung Cancer
      Dr. Karippot is
      Experienced
      . Learn about ALK-Positive Non-Small Cell Lung Cancer.
      See more ALK-Positive Non-Small Cell Lung Cancer experts
    View All 82 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile
    For Patients
    • Our Story
    • How MediFind Works
    • Conditions A-Z
    • Doctor Directory
    • Symptoms Directory
    • Procedures Directory
    • Treatment Directory
    • Drug Directory
    • Infusion Center Finder
    • FAQ
    • Contact Us
    For Providers and Practices
    • Claim Your Profile
    • Newsroom
    Business Solutions
    • Provider
    • Network Solutions
    Additional Resources
    • Consumer Health Data Privacy Policy
    • Privacy Policy
    • Terms of Use
    • Advertising Policy
    • Content Policy
    Subscribe to our newsletter

    Sign up to stay informed about MediFind and get wellness sent your way.

    Close

      By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

      Bullet PinMediFind
      Follow us on
      This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
      © 2026 All Rights Reserved

      Request an Appointment

      If you are experiencing a medical emergency, call 9-1-1.

      MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

      Patient Details

      This information is for the patient who will be seen at the appointment.

        Close

        Returning patient? Use your address on file with the provider.

        Insurance Details

        Please provide information of the primary insurance holder as the practice may require this information to schedule.

        Insurance Provider *
        Insurance ProviderClose

        Appointments Details

        Let’s get more information about your appointment.

                0 / 1000
                0 / 1000
                By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.